SELLAS Life Sciences Group Inc Stock
A very strong showing by SELLAS Life Sciences Group Inc today, with an increase of €0.76 (8.760%) compared to yesterday's price.
The community is currently still undecided about SELLAS Life Sciences Group Inc with 0 Buy predictions and 1 Sell predictions.
A target price of 1 € results in a potential of -89.41% which would mean heavy losses compared to the current price of 9.44 € for SELLAS Life Sciences Group Inc.
Our community identified positive and negative aspects for SELLAS Life Sciences Group Inc stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the SELLAS Life Sciences Group Inc stock. On the other hand our users think that "Innovation" could be a problem in the future.
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Pros and Cons of SELLAS Life Sciences Group Inc in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of SELLAS Life Sciences Group Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 8.760% | -12.851% | -25.812% | 502.778% | 206.173% | 479.439% | 20.556% |
| Beximco Pharmaceuticals Ltd. GDR | -0.940% | 2.941% | 16.667% | 22.664% | 17.188% | 20.413% | -40.341% |
| Eledon Pharmaceuticals Inc. | -1.380% | -9.375% | -13.690% | 8.209% | 126.563% | 137.705% | -46.789% |
| Grifols S.A. ADR | -2.110% | 7.752% | 15.833% | -23.204% | -8.553% | -21.023% | -46.182% |